Dolores Schendel - Medigene Executive
| MDGEFDelisted Stock | USD 2.59 0.00 0.00% |
Executive
Prof. Dr. Dolores J. Schendel has served as Chairman of the Executive Management Board, Chief Executive Officer and Chief Scientific Officer at MediGene AG since February 1, 2016. Previously she served as Chief Scientific Officer and Member of Executive Board of the Company from May 1, 2014. She has served as Director of the Institute of Molecular Immunology at the HelmholtzZentrum Muenchen and Managing Director of Trianta Immunotherapies GmbH. since 2016.
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Phone | 49 89 2000 330 |
| Web | https://www.medigene.com |
Medigene Management Efficiency
The company has return on total asset (ROA) of 0.0887 % which means that it generated a profit of $0.0887 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1768 %, meaning that it generated $0.1768 on every $100 dollars invested by stockholders. Medigene's management efficiency ratios could be used to measure how well Medigene manages its routine affairs as well as how well it operates its assets and liabilities.Medigene AG has accumulated 3.73 M in total debt with debt to equity ratio (D/E) of 0.06, which may suggest the company is not taking enough advantage from borrowing. Medigene AG has a current ratio of 5.92, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Medigene until it has trouble settling it off, either with new capital or with free cash flow. So, Medigene's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medigene AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medigene to invest in growth at high rates of return. When we think about Medigene's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 9 records | EXECUTIVE Age | ||
| James MBA | Geron | N/A | |
| JD Esq | Processa Pharmaceuticals | 50 | |
| Faye MD | Geron | 41 | |
| Aron Feingold | Geron | N/A | |
| Anil Kapur | Geron | 54 | |
| Steven MD | Processa Pharmaceuticals | N/A | |
| Russell MBA | Processa Pharmaceuticals | 65 | |
| Edward Koval | Geron | 62 | |
| James Stanker | Processa Pharmaceuticals | 66 | |
Management Performance
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0887 |
Medigene AG Leadership Team
Elected by the shareholders, the Medigene's board of directors comprises two types of representatives: Medigene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medigene. The board's role is to monitor Medigene's management team and ensure that shareholders' interests are well served. Medigene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medigene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dolores Schendel, Member of the Executive Board, Chief Scientific officer | ||
| Birger Kohlert, Chief Officer | ||
| ErnstLudwig Winnacker, Member of the Supervisory Board | ||
| MBBS BS, CEO Board | ||
| Rene Goedkoop, Acting Officer |
Medigene Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Medigene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0887 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.32 % | |||
| Current Valuation | 30.5 M | |||
| Shares Outstanding | 24.56 M | |||
| Shares Owned By Insiders | 6.66 % | |||
| Shares Owned By Institutions | 4.62 % | |||
| Price To Earning | 5.26 X | |||
| Price To Book | 0.92 X |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Medigene Pink Sheet
If you are still planning to invest in Medigene AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medigene's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |